Manipal Health Enterprises Limited Share Price & Analysis
₹643.25+0.81%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹643.25+0.81%Open
₹631.25High
₹651.10Low
₹625.55Close
₹643.2552W High
₹815.0052W Low
₹597.00Volume
853KLot Size
1Sector
HealthcareMarket Cap
₹80K CrFace Value
₹2Large Cap
Price Chart
Candle
Range
Fundamentals
P/E
90.20Sector P/E
50.20P/B
—EPS
₹7.56ROE
12.70%ROCE
12.10%D/E Ratio
1.53Div Yield
0.00%Book Value
—Strengths
Concerns
- Premium to sector peers (P/E 90.2x vs industry 50.2x)
- Elevated debt levels (D/E 1.5x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Latest News
All newsJefferies bullish on Manipal after ₹9,000 cr acquisitions
*Jefferies is bullish on Manipal Hospitals following its ₹**9,000 crore** acquisition spree.* The brokerage cited enhanced scale and market positioning post-acquisitions, boosting long-term growth prospects. Though integration risks exist, the expanded footprint across key cities strengthens its leadership in the private hospital space. The move may support future fundraising plans, including a potential IPO. 📊 *STOCKS:* | 🏢 *SECTOR:* Hospital | #MEDIUMIMPACT #Hospital
IndiaIPO10 Sept
Manipal Health reports unaudited Q1 FY27 results
*Manipal Health reports unaudited Q1 FY27 results* per a newspaper publication filing. The company released its unaudited financial results for the quarter ended June 30, 2026. Key figures like revenue and net profit were not disclosed in the notice. Final audited results will be issued later per regulatory norms. 📊 *STOCKS:* $MANIPAL | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Earnings
NSE Filing21 Aug
Financials
Quarterly Results
| Metric | Jun 2026 | Mar 2026 | Jun 2025 |
|---|---|---|---|
| Revenue | ₹3.1K Cr 7.3% | ₹2.9K Cr 28.8% | ₹2.2K Cr |
| Op. Profit | ₹737 Cr 6.7% | ₹691 Cr 17.9% | ₹586 Cr |
| OPM | 24.0% 0.0% | 24.0% 7.7% | 26.0% |
| Net Profit | ₹243 Cr 29.9% | ₹187 Cr 26.4% | ₹254 Cr |
| EPS (₹) | 1.96 29.8% | 1.51 30.4% | 2.17 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue | ₹10.3K Cr 25.4% | ₹8.2K Cr 33.5% | ₹6.2K Cr 28.4% | ₹4.8K Cr 20.9% | ₹4.0K Cr 119.2% | ₹1.8K Cr |
| Expenses | ₹7.7K Cr 26.3% | ₹6.1K Cr 36.2% | ₹4.5K Cr 27.3% | ₹3.5K Cr 15.5% | ₹3.1K Cr 105.9% | ₹1.5K Cr |
| Op. Profit | ₹2.6K Cr 22.8% | ₹2.1K Cr 26.4% | ₹1.7K Cr 31.6% | ₹1.3K Cr 38.9% | ₹921 Cr 179.1% | ₹330 Cr |
| OPM | 25.0% 3.8% | 26.0% 3.7% | 27.0% 0.0% | 27.0% 17.4% | 23.0% 27.8% | 18.0% |
| Other Income | ₹111 Cr 17.2% | ₹134 Cr 255.8% | ₹-86 Cr 79.2% | ₹-48 Cr 116.4% | ₹293 Cr 723.4% | ₹-47 Cr |
| Interest | ₹864 Cr 68.8% | ₹512 Cr 12.5% | ₹455 Cr 38.3% | ₹329 Cr 0.9% | ₹326 Cr 59.0% | ₹205 Cr |
| Depreciation | ₹680 Cr 34.1% | ₹507 Cr 27.7% | ₹397 Cr 26.0% | ₹315 Cr 23.0% | ₹256 Cr 39.9% | ₹183 Cr |
| PBT | ₹1.2K Cr 5.2% | ₹1.2K Cr 66.7% | ₹745 Cr 27.1% | ₹586 Cr 7.3% | ₹632 Cr 701.9% | ₹-105 Cr |
| Tax % | 22.0% 69.2% | 13.0% 53.6% | 28.0% 3.7% | 27.0% 92.9% | 14.0% 53.3% | 30.0% |
| Net Profit | ₹917 Cr 15.2% | ₹1.1K Cr 103.0% | ₹533 Cr 24.2% | ₹429 Cr 20.8% | ₹542 Cr 492.8% | ₹-138 Cr |
| EPS (₹) | 7.56 18.0% | 9.22 76.0% | 5.24 38.6% | 3.78 20.8% | 4.77 456.0% | -1.34 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Liabilities | ||||||
| Equity Capital | ₹236 Cr 206.5% | ₹77 Cr 1.3% | ₹76 Cr 0.0% | ₹76 Cr 0.0% | ₹76 Cr 10.1% | ₹69 Cr |
| Reserves | ₹8.2K Cr 41.9% | ₹5.8K Cr 46.4% | ₹3.9K Cr 24.4% | ₹3.2K Cr 15.9% | ₹2.7K Cr 156.8% | ₹1.1K Cr |
| Borrowings | ₹12.9K Cr 101.5% | ₹6.4K Cr 24.5% | ₹5.1K Cr 134.9% | ₹2.2K Cr 8.3% | ₹2.0K Cr 28.1% | ₹1.6K Cr |
| Other Liabilities | ₹3.4K Cr 107.8% | ₹1.7K Cr 2.9% | ₹1.6K Cr 31.0% | ₹2.3K Cr 7.3% | ₹2.5K Cr 91.6% | ₹1.3K Cr |
| Total Liabilities | ₹24.7K Cr 78.1% | ₹13.9K Cr 29.1% | ₹10.8K Cr 38.6% | ₹7.8K Cr 5.7% | ₹7.3K Cr 82.6% | ₹4.0K Cr |
Assets | ||||||
| Fixed Assets | ₹18.8K Cr 90.9% | ₹9.8K Cr 20.4% | ₹8.2K Cr 70.5% | ₹4.8K Cr 4.4% | ₹4.6K Cr 101.1% | ₹2.3K Cr |
| CWIP | ₹795 Cr 29.5% | ₹614 Cr 1361.9% | ₹42 Cr 95.9% | ₹1.0K Cr 5.1% | ₹1.1K Cr 164.3% | ₹412 Cr |
| Investments | ₹2.7K Cr 50.6% | ₹1.8K Cr 58.4% | ₹1.1K Cr 8.0% | ₹1.0K Cr 35.2% | ₹768 Cr 39.4% | ₹551 Cr |
| Other Assets | ₹2.5K Cr 49.9% | ₹1.7K Cr 16.6% | ₹1.4K Cr 58.1% | ₹908 Cr 0.1% | ₹907 Cr 15.7% | ₹784 Cr |
| Total Assets | ₹24.7K Cr 78.1% | ₹13.9K Cr 29.1% | ₹10.8K Cr 38.6% | ₹7.8K Cr 5.7% | ₹7.3K Cr 82.6% | ₹4.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Operating CF | ₹2.1K Cr 32.4% | ₹1.6K Cr 13.0% | ₹1.4K Cr 20.9% | ₹1.1K Cr 42.7% | ₹805 Cr 89.0% | ₹426 Cr |
| Investing CF | ₹-7.0K Cr 176.1% | ₹-2.5K Cr 200.7% | ₹-846 Cr 14.9% | ₹-994 Cr 41.9% | ₹-1.7K Cr 810.1% | ₹-188 Cr |
| Financing CF | ₹5.0K Cr 448.0% | ₹904 Cr 461.6% | ₹-250 Cr 73.6% | ₹-144 Cr 115.3% | ₹941 Cr 436.1% | ₹-280 Cr |
| Net Cash Flow | ₹8 Cr 111.4% | ₹-70 Cr 123.9% | ₹293 Cr 2341.7% | ₹12 Cr 64.7% | ₹34 Cr 181.0% | ₹-42 Cr |
| Free Cash Flow | ₹767 Cr 47.5% | ₹520 Cr 51.0% | ₹1.1K Cr 29.0% | ₹823 Cr 30.8% | ₹629 Cr 88.3% | ₹334 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Debtor Days | 33d 17.9% | 28d 3.7% | 27d 12.5% | 24d 11.1% | 27d 3.8% | 26d |
| Inventory Days | 29d 0.0% | 29d 3.3% | 30d 30.4% | 23d 17.9% | 28d 40.0% | 20d |
| Days Payable | 253d 3.3% | 245d 25.8% | 330d 16.6% | 283d 15.0% | 246d 33.7% | 371d |
| Cash Conv. Cycle | -190d 1.1% | -188d 31.1% | -273d 15.7% | -236d 24.2% | -190d 41.5% | -325d |
| Working Capital Days | -70d 75.0% | -40d 31.0% | -58d 3.6% | -56d 50.4% | -113d 18.9% | -95d |
| ROCE | 12.0% 25.0% | 16.0% 11.1% | 18.0% 5.3% | 19.0% 5.6% | 18.0% | — |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Manipal Health Enterprises Limited share price today?
Manipal Health Enterprises Limited (MANIPALHOS) is currently trading at ₹643.25 on NSE, up 0.81% as of the last market session. Prices update daily after market close on MarketNetra.
Is Manipal Health Enterprises Limited available in F&O (Futures & Options)?
Yes, Manipal Health Enterprises Limited (MANIPALHOS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Manipal Health Enterprises Limited 52-week high and low?
Manipal Health Enterprises Limited's 52-week high is ₹815 and the 52-week low is ₹597. The current price of ₹643.25 is 21.1% below the 52W high.
What is Manipal Health Enterprises Limited P/E ratio?
Manipal Health Enterprises Limited's current P/E ratio is 90.2. This indicates the market is paying ₹90.2 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Manipal Health Enterprises Limited options?
Manipal Health Enterprises Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade MANIPALHOS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.